Incidence of AGVHD in 63 patients receiving DLI for relapse after allogeneic SCT for CML: univariate analysis of potential factors
| Variable . | AGVHD Grade . | P* . | |
|---|---|---|---|
| 0 to I . | II to IV . | ||
| AGVHD after SCT | |||
| 0 to I | 28 | 7 | .43 |
| II to IV | 20 | 8 | |
| Patient-donor sex | |||
| Matched | 32 | 3 | .003 |
| Mismatched | 16 | 11 | |
| Patient-donor CMV serostatus† | |||
| Negative | 20 | 1 | .016 |
| Positive | 28 | 13 | |
| GVHD prophylaxis at SCT‡ | |||
| Non-TCD | 19 | 1 | .017 |
| TCD | 29 | 14 | |
| Patient age at time of DLI | |||
| Younger than 36 y | 28 | 4 | .032 |
| Older than 36 y | 20 | 11 | |
| Type of DLI regimen | |||
| BDR | 16 | 11 | .006 |
| EDR | 32 | 4 | |
| Molecular remission after DLI | |||
| Yes | 35 | 13 | .64 |
| No | 10 | 5 | |
| Donor type | |||
| Identical sibling | 24 | 7 | .82 |
| Matched unrelated | 24 | 8 | |
| Type of relapse at time of DLI | |||
| Molecular | 7 | 0 | .40 |
| Cytogenetic | 15 | 5 | |
| Hem-CP | 19 | 8 | |
| Hem-AP | 7 | 2 | |
| Interval SCT to relapse | |||
| Shorter than 12 mo | 24 | 9 | .50 |
| 12 mo or longer | 24 | 6 | |
| Interval relapse to DLI | |||
| Shorter than 12 mo | 23 | 6 | .59 |
| 12 mo or longer | 25 | 9 | |
| Interval SCT to DLI | |||
| Shorter than 24 mo | 22 | 9 | .33 |
| 24 mo or longer | 22 | 6 | |
| Variable . | AGVHD Grade . | P* . | |
|---|---|---|---|
| 0 to I . | II to IV . | ||
| AGVHD after SCT | |||
| 0 to I | 28 | 7 | .43 |
| II to IV | 20 | 8 | |
| Patient-donor sex | |||
| Matched | 32 | 3 | .003 |
| Mismatched | 16 | 11 | |
| Patient-donor CMV serostatus† | |||
| Negative | 20 | 1 | .016 |
| Positive | 28 | 13 | |
| GVHD prophylaxis at SCT‡ | |||
| Non-TCD | 19 | 1 | .017 |
| TCD | 29 | 14 | |
| Patient age at time of DLI | |||
| Younger than 36 y | 28 | 4 | .032 |
| Older than 36 y | 20 | 11 | |
| Type of DLI regimen | |||
| BDR | 16 | 11 | .006 |
| EDR | 32 | 4 | |
| Molecular remission after DLI | |||
| Yes | 35 | 13 | .64 |
| No | 10 | 5 | |
| Donor type | |||
| Identical sibling | 24 | 7 | .82 |
| Matched unrelated | 24 | 8 | |
| Type of relapse at time of DLI | |||
| Molecular | 7 | 0 | .40 |
| Cytogenetic | 15 | 5 | |
| Hem-CP | 19 | 8 | |
| Hem-AP | 7 | 2 | |
| Interval SCT to relapse | |||
| Shorter than 12 mo | 24 | 9 | .50 |
| 12 mo or longer | 24 | 6 | |
| Interval relapse to DLI | |||
| Shorter than 12 mo | 23 | 6 | .59 |
| 12 mo or longer | 25 | 9 | |
| Interval SCT to DLI | |||
| Shorter than 24 mo | 22 | 9 | .33 |
| 24 mo or longer | 22 | 6 | |
TCD indicates in vitro or in vivo T-cell depletion with Campath monoclonal antibodies; EDR, escalating-dose regimen; BDR, bulk-dose regimen; Hem, hematologic; CP, chronic phase; AP, accelerated phase.
Chi-squared or Fisher exact test.
CMV serostatus negative: when both donor and recipient were negative; CMV serostatus positive if only donor or only recipient or both were positive.
GVHD prophylaxis at time of transplantation.